DIGITALX LIMITED — Director's Dealing 2020

Aug 31, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	DigitalX Limited
ABN	59 009 575 035

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter Irwin Rubinstein
Date of last notice	12 December 2019

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest	Irwin Biotech Nominees Pty Ltd ATF BIOA Trust.
(including registered holder)	Peter Irwin Rubinstein is the sole director and
Note: Provide details of the circumstances giving rise to the relevant interest.	shareholder of Irwin Biotech Nominees Pty Ltd and a beneficiary of the BIOA Trust.
Date of change	1 September 2020

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

										324	324
	No. of secu	rities hel	d prior to change			Direct 617,284 each on Indirec	Subscription or before 1 S t	Options exerc eptember 2020	isable at $0.0	324
						15,266, 3,000,0 7,200,0 3,400,0	296 Fully Paid 00 Fully Paid 00 Fully Paid 00 Incentive	Ordinary Share Ordinary Shares Ordinary Shares Options exerci	s1 2 3 sable at $0.0	324
						each on 1,000,0 on or be 1,500,0 on or be 2,000,0	or before 18 00 Unlisted O fore 10 Dece 00 Unlisted O fore 10 Dece 00 Unlisted O	September 202 ptions exercisa mber 20231 ptions exercisa mber 20231 ptions exercisa	01 ble at $0.22 ble at $0.25 ble at $0.30	each each each
						on or be 3,000,0 perform or befor 1. Held b	fore the date 00 Perform ance-based v e 12 Decemb y Irwin Biotech	10 December 2 ance Rights esting condition er 20221 Nominees Pty Lt	0231 , subject s, and expirin d ATF BIOA Tru	to g on st.
						2. Held b 3. Held b	y RIP Opportun y ValueAdmin.	ities Pty Ltd ATF Com Pty Ltd.	PIR Super Fun	d.
	Class					Fully Pa Subscri before 1	id Ordinary S ption Options September 2	hares exercisable at $ 020	0.0324 each o	n or
						Incentive Options exercisable at $0.0324 each on or before 18 September 20201
	Number acquired					4,017,284 Fully Paid Ordinary Shares
	Number disposed					617,284 Subscription Options exercisable at $0.0324 each on or before 1 September 2020 3,400,000 Incentive Options exercisable at $0.0324 each on or before 18 September 2020
	Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation					$130,160 ($0.0324 per Share)

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

No. of securities held after change	Direct
	617,284 Fully Paid Ordinary Shares
	Indirect
	18,666,296 Fully Paid Ordinary Shares1
	3,000,000 Fully Paid Ordinary Shares2
	7,200,000 Fully Paid Ordinary Shares3
	1,000,000 Unlisted Options exercisable at $0.22 each
	on or before 10 December 20231
	1,500,000 Unlisted Options exercisable at $0.25 each
	on or before 10 December 20231
	2,000,000 Unlisted Options exercisable at $0.30 each
	on or before the date 10 December 20231
	3,000,000 Performance Rights, subject	to
	performance-based vesting conditions, and expiring on
	or before 12 December 20221
	1. Held by Irwin Biotech Nominees Pty Ltd ATF BIOA Trust.
	2. Held by RIP Opportunities Pty Ltd ATF PIR Super Fund.
	3. Held by ValueAdmin.Com Pty Ltd.
Nature of change	4,017,284 Fully Paid Ordinary Shares issued upon the
Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	exercise of 617,284 Subscription Options expiring 1 September 2020 and 3,400,000 Incentive Options expiring 18 September 2020

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest
Name of registered holder
(if issued securities)
Date of change
No. and class of securities to which
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3

Appendix 3Y Change of Director’s Interest Notice

Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed	No
above traded during a+closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade
to proceed during this period?
If prior written clearance was provided, on what date was this
provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 4

01/01/2011